GlassScriptPhysician profile
Sarah E Stone
NPI 1982088340
$2,036.85
in general payments reported to CMS, 2019-2025
25 companies · $51.32 in 2025
The $51.32 reported for 2025 was less than what a typical Women'S Health (Nurse Practitioner) provider received nationally (typical 2025 total: $123).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $501 · 2022: $222 · 2023: $866 · 2024: $396 · 2025: $51.32.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,134 · Education: $180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,133.96 |
| Education | $179.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $457.28 | 2023-2024 | Veozah, Myrbetriq |
| Abbvie INC. | $288.35 | 2021-2023 | |
| Amgen INC. | $225.58 | 2021-2025 | Evenity, Prolia, Prolia |
| Shield Therapeutics INC | $211.45 | 2023-2024 | Accrufer |
| Bayer Healthcare Pharmaceuticals INC. | $94.38 | 2021-2023 | |
| Evofem Biosciences, INC. | $93.04 | 2021-2023 | Phexxi |
| Organon LLC | $80.74 | 2021-2023 | Nexplanon |
| Baxter Healthcare | $67.66 | 2022-2023 | Perclot |
| Myriad Women'S Health, INC. | $59.47 | 2023 | Myrisk |
| Biohaven Pharmaceuticals, INC. | $54.83 | 2021 | |
| Avion Pharmaceuticals | $51.50 | 2023 | Balcoltra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $50.26 | 2022-2023 | Trulance, Xifaxan |
| Novo Nordisk INC | $43.42 | 2021 | |
| Pacira Pharmaceuticals Incorporated | $41.65 | 2022-2023 | Exparel |
| Aspira Women'S Health INC | $28.71 | 2024 | Ova1 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Therapeuticsmd, INC. | $28.19 | 2021 | |
| Lsi Solutions INC | $25.43 | 2023 | Fornisee |
| Bausch Health US, LLC | $18.86 | 2024 | Wellbutrin, Aplenzin |
| Grifols USA, LLC | $18.66 | 2025 | Gamunex-C |
| Sumitomo Pharma America, INC. | $18.06 | 2024 | Myfembree |
| Sage Therapeutics, LLC | $17.33 | 2024 | |
| Radius Health, INC. | $16.50 | 2024 | Tymlos |
| Hologic Sales and Service, LLC | $16.06 | 2023 | Acessa Provu System |
| Merck Sharp & Dohme LLC | $15.15 | 2021 | |
| Lilly USA, LLC | $14.29 | 2024 | Zepbound |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Stone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.